<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689206</url>
  </required_header>
  <id_info>
    <org_study_id>204836</org_study_id>
    <nct_id>NCT02689206</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent</brief_title>
  <official_title>A 29-day, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor,
      currently being investigated as a treatment for anemia associated with chronic kidney
      disease. GSK1278863 has been given as a once daily regimen in clinical studies to date.
      However, physicians in countries that use a three-times weekly hemodialysis schedule prefer
      to give the anemia medicine at the same time as the dialysis session. This study will test
      how well GSK1278863 can maintain hemoglobin levels when given three-times weekly, for 29
      days.

      This study will describe the relationship between hemoglobin and GSK1278863 given three-times
      weekly. The data from this study will allow for conversion of once daily doses to three-times
      weekly doses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 17, 2016</start_date>
  <completion_date type="Actual">January 25, 2017</completion_date>
  <primary_completion_date type="Actual">January 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hgb Levels at Day 29</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Blood samples were collected from participants for measurement of Hgb values. Baseline is the average of Hgb measured at Week -2 and Day 1 visits. Change from Baseline at Day 29 was defined as post dose value at Day 29 minus Baseline value. The analysis was performed on intent-to-treat (ITT) Population which comprised of all randomized participants who received at least one dose of study treatment, had a Baseline and at least one corresponding on treatment assessment, including Hgb.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO)</measure>
    <time_frame>Baseline and up to Day 29</time_frame>
    <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on EPO. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at each given post-Baseline time point was calculated and the maximum change from Baseline was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)</measure>
    <time_frame>Baseline and up to Day 29</time_frame>
    <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on VEGF. Day 1 values were considered as Baseline values. The percent change from Baseline at each given post-Baseline time point was calculated (expressed as geometric mean) and the maximum percent change from Baseline was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hepcidin at Day 29</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on hepcidin. Day 1 values were considered as Baseline values. The Percent change from Baseline at Day 29 post-Baseline time point was calculated and expressed as geometric mean and the maximum change from Baseline was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematocrit Levels</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on hematocrit. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Red Blood Cell (RBC) Count</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on RBC count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reticulocyte Count</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on reticulocyte count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reticulocyte Hemoglobin (CHr)</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on CHr. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) and AUC From Time Zero to Infinity (AUC[0-inf]) of Dapro</measure>
    <time_frame>Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a &quot;Day 1&quot; profile for non-compartmental analysis (NCA). Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. The analysis was performed on PK Population, which comprised of all participants from whom a PK sample has been obtained and analyzed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration of Dapro in Plasma (Cmax)</measure>
    <time_frame>Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a &quot;Day 1&quot; profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (Tmax) and Apparent Terminal Half-life (t1/2) of Dapro</measure>
    <time_frame>Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a &quot;Day 1&quot; profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Reasons of study treatment discontinuation included adverse events (AEs), protocol deviation, participants reached protocol defined stopping criteria, physician decision and withdrawal by participants. Number of participants who discontinued study treatment are presented. Analysis was performed on Safety Population which comprised of all participants who received at least one dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AEs and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium, Potassium, Glucose, Calcium, Phosphate Levels in Blood at Indicated Time Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Serum sodium, potassium, glucose, corrected calcium and phosphate levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin and Protein Levels in Blood at Indicated Tme Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Serum albumin and protein levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (Alk. Phosph) Levels in Blood at Indicated Time Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Serum ALT, AST and alk. phosph. levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin, Direct Bilirubin and Indirect Bilirubin Levels in Blood at Indicated Time Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Serum bilirubin, direct bilirubin and indirect bilirubin levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sodium, Potassium, Glucose, Calcium and Phosphate Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including sodium, potassium, glucose, calcium and phosphate. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin and Protein Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ALT, AST, Alk. Phosph. Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT, AST, Alk. phosph. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bilirubin, Direct Bilirubin, Indirect Bilirubin Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including bilirubin, direct bilirubin and indirect bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes, Neutrophils, Basophils, Eosinophils,Lymphocytes, Monocytes, Platelet Levels in Blood at Indicated Time Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Serum leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelet levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Hemoglobin (MCH) Levels in Blood at Indicated Time Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Serum MCH levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Hemoglobin Concentration (MCHC) Levels in Blood at Indicated Time Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Serum MCHC levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Volume (MCV) Levels in Blood at Indicated Time Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Serum MCV levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Distribution Width Levels in Blood at Indicated Time Points</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Erythrocyte distribution width levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MCH Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MCHC Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MCV Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erythrocyte Distribution Width Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte distribution width. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Leukocytes, Neutrophils, Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets Levels</measure>
    <time_frame>Baseline and up to Day 43</time_frame>
    <description>Blood samples were collected from participants to evaluate clinical hematology parameters including leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes, platelets. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Indicated Time Points</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT interval. Number of participants who had abnormal non clinically significant (NCS) and abnormal clinically significant (CS) ECG findings at Baseline (Week -4) and Day 29 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ECG Mean Heart Rate</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure HR. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval and QTcB</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure PR interval, QRS duration, QT interval and QTcB. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Pre-dialysis and Post-dialysis</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair at specific time points. SBP and DBP were measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate Values at Pre-dialysis and Post-dialysis</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Vital sign measurements including pulse rate values were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Values at Post-dialysis</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Vital sign measurements including weight values were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SBP and DBP Values at Pre-dialysis and Post-dialysis</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair. SBP and DBP were measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as SBP and DBP value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate Value at Pre-dialysis and Post-dialysis</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Vital sign measurements including pulse rate were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as pulse rate value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as pulse rate value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight at Post-dialysis</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Vital sign measurements including weight were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>GSK1278863 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1278863 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1278863 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1278863 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1278863</intervention_name>
    <description>GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.</description>
    <arm_group_label>GSK1278863 10 mg</arm_group_label>
    <arm_group_label>GSK1278863 30 mg</arm_group_label>
    <arm_group_label>GSK1278863 15 mg</arm_group_label>
    <arm_group_label>GSK1278863 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1278863 matching Placebo</intervention_name>
    <description>GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than or equal to 18 years of age, at the time of signing the informed consent.

          -  Hemoglobin: Stable Hemoglobin 9.0 - 11.5 gram per deciliter (g/dL).

          -  Dialysis frequency: On hemodialysis (HD, hemofiltration or hemodiafiltration) three to
             five times weekly for at least 4 weeks prior to Day -28 Screening through Day 29.

          -  Dialysis adequacy: A single pool Kt/Vurea of &gt;=1.2 based on a historical value
             obtained within the prior three months in order to ensure the adequacy of dialysis. If
             Kt/Vurea is not available, then an average of the last 2 values of urea reduction
             ratio (URR) of at least 65 percent. NOTE: Only needs confirming at Day -28.

          -  Erythropoiesis-stimulating agent (ESA)dose: Treated with the same ESA (epoetins or
             their biosimilars, or darbepoetin or methoxy polyethylene glycol [PEG]-epoetin beta)
             with total weekly dose varying by no more than 50 percent during the 4 weeks prior to
             Day -28.

          -  Iron replacement therapy: Subjects may be on stable maintenance oral or intravenous
             (IV) (&lt;=100 milligram (mg)/week) iron supplementation. If subjects are on oral or IV
             iron, then doses must be stable for the 4 weeks prior to Day -28, during the screening
             phase, and through the 29 days of treatment.

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the consent form and in study protocol.

        Exclusion Criteria:

          -  Dialysis modality: Planned change from HD to peritoneal dialysis within the study time
             period.

          -  Renal transplant: Planned for living-related kidney transplant.

          -  High ESA dose: An epoetin dose of &gt;=360 international unit (IU)/kilogram (kg)/week IV
             or &gt;=250 IU/kg/week subcutaneous (SC) or darbepoetin dose of &gt;=1.8 microgram
             (mcg)/kg/week IV or SC or methoxy PEG-epoetin beta dose of &gt;= 2.2 mcg/kg/week within
             the prior 8 weeks through Day 1 (randomization).

          -  Administration of methoxy PEG-epoetin beta within the prior 4 weeks through Day 1
             (randomization).

          -  Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to
             Screening through Day 1 (randomization).

          -  Stroke or transient ischemic attack: Within 8 weeks prior to Screening though Day 1
             (randomization).

          -  Heart failure: Class IV heart failure, as defined by the New York Heart Association
             (NYHA) functional classification system diagnosed prior to Screening through Day 1
             (randomization).

          -  Correction of Q-T Interval using Bazett's formula (QTcB): QTcB &gt;500 millisecond (msec)
             or QTcB &gt;530 msec in subjects with Bundle Branch Block. There is no correction of Q-T
             Interval (QTc) exclusion for subjects with a predominantly paced rhythm.

          -  Inflammatory disease: Active chronic inflammatory disease that could impact
             erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis,
             celiac disease) diagnosed prior to Screening through Day 1 (randomization).

          -  Hematological disease: Any hematological disease including those affecting platelets,
             white or red blood cells (e.g., sickle cell anemia, myelodysplastic syndromes,
             hematological malignancy, myeloma, hemolytic anemia and thalassemia), coagulation
             disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other
             cause of anemia of chronic disease other than renal disease diagnosed prior to
             Screening though Day 1 (randomization).

          -  Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the
             exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening
             of abnormal liver function tests [alanine transaminase (ALT) or aspartate transaminase
             (AST) &gt;2x upper limit of normal (ULN) or total bilirubin &gt;1.5xULN]; or other hepatic
             abnormalities that in the opinion of the investigator would preclude the subject from
             participating in the study.

        NOTE: Those with Hepatitis B or Hepatitis C are eligible provided these exclusions are not
        met.

          -  Major surgery: Major surgery (excluding vascular access surgery) within the 8 weeks
             prior to Screening, during the Screening phase, or planned during the study.

          -  Transfusion: Blood transfusion within the 8 weeks prior to Screening, during the
             Screening phase or an anticipated need for blood transfusion during the study.

          -  Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or
             esophageal ulcer disease OR clinically significant GI bleeding within the 8 weeks
             prior to Screening through Day 1 (randomization).

          -  Acute Infection: Clinical evidence of acute infection or history of infection
             requiring IV antibiotic therapy within the 4 weeks prior to Screening through Day 1
             (randomization). NOTE: IV antibiotics as prophylaxis are allowed.

          -  Malignancy: History of malignancy within the two years prior to randomization or
             currently receiving treatment for cancer, or has a known &gt;=4 centimeter complex kidney
             cyst (i.e. Bosniak Category II F, III of IV). NOTE: ONLY exception is squamous cell or
             basal cell carcinoma of the skin that has been definitively treated &gt;=8 weeks prior to
             Screening.

          -  Severe allergic reactions: History of severe allergic or anaphylactic reactions or
             hypersensitivity to excipients in the investigational product

          -  Drugs and supplements: Use of any prescription or non-prescription drugs or dietary
             supplements that are prohibited (as per protocol) from Screening until the Follow-up
             Visit.

          -  Prior investigational product exposure: The Subject has participated in a clinical
             trial and has received an experimental investigational product within the prior 30
             days from Screening through Day 1 (randomization).

          -  Other conditions: Any other condition, clinical or laboratory abnormality, or
             examination finding that the investigator considers would put the subject at
             unacceptable risk, which may affect study compliance or prevent understanding of the
             aims or investigational procedures or possible consequences of the study.

          -  Females ONLY: A female subject is not eligible to participate if she is pregnant [as
             confirmed by a positive serum human chorionic gonadotrophin (hCG) test for females of
             reproductive potential (FRP) only], breastfeeding, and if of reproductive potential
             does not agree to follow one of the options listed in the GSK Modified List of Highly
             Effective Methods for Avoiding Pregnancy in FRP.

          -  Vitamin B12: At or below the lower limit of the reference range (may rescreen in a
             minimum of 8 weeks).

          -  Folate: &lt;2.0 nanogram (ng) per millilitre (mL) (4.5 nanomole/liter [L]) (may rescreen
             in a minimum of 4 weeks).

          -  Ferritin: &lt;100 ng/mL (&lt;100 mcg/L).

          -  Transferrin saturation (TSAT): &lt;20 percent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>3801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2R 0X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64295</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>129327</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mytischi</city>
        <zip>141009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omsk</city>
        <zip>644112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Penza</city>
        <zip>440034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almer√≠a</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Granollers, Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leon</city>
        <zip>24007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manises (Valencia)</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Terrassa, Barcelona</city>
        <zip>08223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <results_first_submitted>January 23, 2018</results_first_submitted>
  <results_first_submitted_qc>April 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2018</results_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Erythropoiesis-stimulating agent</keyword>
  <keyword>GSK1278863</keyword>
  <keyword>Safety</keyword>
  <keyword>Hemodialysis-dependent anemia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants on Hemodialysis (HD) with anemia associated with chronic kidney disease (CKD) switching from Erythropoiesis-Stimulating Agent (ESA) treatment were recruited in this randomized, dose-ranging study. Participants with hemoglobin (Hgb) values between 9.0- 11.5 grams per deciliter (g/dL) were considered as eligible for recruitment.</recruitment_details>
      <pre_assignment_details>A total of 211 participants were screened; of which 108 were screen failures and 103 were randomized to receive at least one dose of either placebo or 10, 15, 25 or 30 milligrams (mg) of daprodustat (dapro). One participant who was randomized to the placebo group, erroneously received 25 mg dapro treatment throughout the 29-day treatment period</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="P2">
          <title>Dapro 10 mg</title>
          <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="P3">
          <title>Dapro 15 mg</title>
          <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="P4">
          <title>Dapro 25 mg</title>
          <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="P5">
          <title>Dapro 30 mg</title>
          <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Reached stopping criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="B2">
          <title>Dapro 10 mg</title>
          <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="B3">
          <title>Dapro 15 mg</title>
          <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="B4">
          <title>Dapro 25 mg</title>
          <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="B5">
          <title>Dapro 30 mg</title>
          <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="22"/>
            <count group_id="B6" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="13.06"/>
                    <measurement group_id="B2" value="63.6" spread="16.98"/>
                    <measurement group_id="B3" value="59.5" spread="12.26"/>
                    <measurement group_id="B4" value="67.2" spread="15.22"/>
                    <measurement group_id="B5" value="65.4" spread="13.97"/>
                    <measurement group_id="B6" value="63.4" spread="14.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race customized</title>
              <category_list>
                <category>
                  <title>African American/African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian Or Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - Central/South Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian Or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White- Arabic/North African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hgb Levels at Day 29</title>
        <description>Blood samples were collected from participants for measurement of Hgb values. Baseline is the average of Hgb measured at Week -2 and Day 1 visits. Change from Baseline at Day 29 was defined as post dose value at Day 29 minus Baseline value. The analysis was performed on intent-to-treat (ITT) Population which comprised of all randomized participants who received at least one dose of study treatment, had a Baseline and at least one corresponding on treatment assessment, including Hgb.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hgb Levels at Day 29</title>
          <description>Blood samples were collected from participants for measurement of Hgb values. Baseline is the average of Hgb measured at Week -2 and Day 1 visits. Change from Baseline at Day 29 was defined as post dose value at Day 29 minus Baseline value. The analysis was performed on intent-to-treat (ITT) Population which comprised of all randomized participants who received at least one dose of study treatment, had a Baseline and at least one corresponding on treatment assessment, including Hgb.</description>
          <population>ITT Population</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.646"/>
                    <measurement group_id="O2" value="-0.19" spread="1.750"/>
                    <measurement group_id="O3" value="-0.13" spread="1.088"/>
                    <measurement group_id="O4" value="0.64" spread="1.453"/>
                    <measurement group_id="O5" value="0.55" spread="1.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
            <estimate_desc>Analysis using a Repeated Measures Model with terms included for baseline, treatment, time and treatment*time. Model-adjusted treatment difference of dapro 10 mg arm from Placebo along with 95 percent CI are presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>Analysis using a Repeated Measures Model with terms included for baseline, treatment, time and treatment*time. Model-adjusted treatment difference of dapro 15 mg arm from Placebo along with 95 percent CI are presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
            <estimate_desc>Analysis using a Repeated Measures Model with terms included for baseline, treatment, time and treatment*time. Model-adjusted treatment difference of dapro 25 mg arm from Placebo along with 95 percent CI are presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
            <estimate_desc>Analysis using a Repeated Measures Model with terms included for baseline, treatment, time and treatment*time. Model-adjusted treatment difference of dapro 30 mg arm from Placebo along with 95 percent CI are presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO)</title>
        <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on EPO. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at each given post-Baseline time point was calculated and the maximum change from Baseline was determined.</description>
        <time_frame>Baseline and up to Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO)</title>
          <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on EPO. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at each given post-Baseline time point was calculated and the maximum change from Baseline was determined.</description>
          <population>ITT Population</population>
          <units>International unit per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.761" spread="132.6875"/>
                    <measurement group_id="O2" value="2.255" spread="84.8921"/>
                    <measurement group_id="O3" value="73.369" spread="95.9772"/>
                    <measurement group_id="O4" value="302.529" spread="469.8312"/>
                    <measurement group_id="O5" value="477.644" spread="388.9757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)</title>
        <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on VEGF. Day 1 values were considered as Baseline values. The percent change from Baseline at each given post-Baseline time point was calculated (expressed as geometric mean) and the maximum percent change from Baseline was determined.</description>
        <time_frame>Baseline and up to Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)</title>
          <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on VEGF. Day 1 values were considered as Baseline values. The percent change from Baseline at each given post-Baseline time point was calculated (expressed as geometric mean) and the maximum percent change from Baseline was determined.</description>
          <population>ITT Population</population>
          <units>Nanograms per liter (ng/L)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.35" lower_limit="-0.48" upper_limit="45.55"/>
                    <measurement group_id="O2" value="43.75" lower_limit="16.44" upper_limit="77.45"/>
                    <measurement group_id="O3" value="32.16" lower_limit="-4.77" upper_limit="83.41"/>
                    <measurement group_id="O4" value="53.34" lower_limit="17.17" upper_limit="100.68"/>
                    <measurement group_id="O5" value="76.09" lower_limit="34.89" upper_limit="129.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hepcidin at Day 29</title>
        <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on hepcidin. Day 1 values were considered as Baseline values. The Percent change from Baseline at Day 29 post-Baseline time point was calculated and expressed as geometric mean and the maximum change from Baseline was determined.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hepcidin at Day 29</title>
          <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on hepcidin. Day 1 values were considered as Baseline values. The Percent change from Baseline at Day 29 post-Baseline time point was calculated and expressed as geometric mean and the maximum change from Baseline was determined.</description>
          <population>ITT Population</population>
          <units>Micrograms per liter (¬µg/L)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.81" lower_limit="-12.68" upper_limit="87.08"/>
                    <measurement group_id="O2" value="35.37" lower_limit="-1.13" upper_limit="85.34"/>
                    <measurement group_id="O3" value="3.83" lower_limit="-17.85" upper_limit="31.24"/>
                    <measurement group_id="O4" value="-36.74" lower_limit="-49.91" upper_limit="-20.12"/>
                    <measurement group_id="O5" value="-36.09" lower_limit="-57.24" upper_limit="-4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematocrit Levels</title>
        <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on hematocrit. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit Levels</title>
          <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on hematocrit. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
          <population>ITT Population</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0218" spread="0.02469"/>
                    <measurement group_id="O2" value="-0.0127" spread="0.05396"/>
                    <measurement group_id="O3" value="-0.0149" spread="0.05379"/>
                    <measurement group_id="O4" value="0.0150" spread="0.04511"/>
                    <measurement group_id="O5" value="0.0215" spread="0.03852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Red Blood Cell (RBC) Count</title>
        <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on RBC count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Red Blood Cell (RBC) Count</title>
          <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on RBC count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
          <population>ITT Population</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.263"/>
                    <measurement group_id="O2" value="-0.12" spread="0.494"/>
                    <measurement group_id="O3" value="-0.13" spread="0.500"/>
                    <measurement group_id="O4" value="0.12" spread="0.420"/>
                    <measurement group_id="O5" value="0.15" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Reticulocyte Count</title>
        <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on reticulocyte count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reticulocyte Count</title>
          <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on reticulocyte count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
          <population>ITT Population</population>
          <units>Percentage of reticulocyte</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.848"/>
                    <measurement group_id="O2" value="-0.11" spread="0.803"/>
                    <measurement group_id="O3" value="-0.04" spread="0.581"/>
                    <measurement group_id="O4" value="0.43" spread="0.547"/>
                    <measurement group_id="O5" value="0.09" spread="0.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Reticulocyte Hemoglobin (CHr)</title>
        <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on CHr. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reticulocyte Hemoglobin (CHr)</title>
          <description>Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on CHr. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.</description>
          <population>ITT Population</population>
          <units>Picograms (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="1.375"/>
                    <measurement group_id="O2" value="0.23" spread="1.335"/>
                    <measurement group_id="O3" value="0.26" spread="1.103"/>
                    <measurement group_id="O4" value="0.23" spread="1.040"/>
                    <measurement group_id="O5" value="0.59" spread="1.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) and AUC From Time Zero to Infinity (AUC[0-inf]) of Dapro</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a ‚ÄúDay 1‚Äù profile for non-compartmental analysis (NCA). Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. The analysis was performed on PK Population, which comprised of all participants from whom a PK sample has been obtained and analyzed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29</time_frame>
        <population>PK Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) and AUC From Time Zero to Infinity (AUC[0-inf]) of Dapro</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a ‚ÄúDay 1‚Äù profile for non-compartmental analysis (NCA). Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. The analysis was performed on PK Population, which comprised of all participants from whom a PK sample has been obtained and analyzed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>PK Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>hour into nanograms/milliliter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-t); n= 19, 15, 16, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.7" spread="91.4"/>
                    <measurement group_id="O2" value="416.7" spread="168.6"/>
                    <measurement group_id="O3" value="513.9" spread="396.1"/>
                    <measurement group_id="O4" value="1010" spread="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-inf); n= 12, 9, 8, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348.2" spread="78.2"/>
                    <measurement group_id="O2" value="383.5" spread="142.7"/>
                    <measurement group_id="O3" value="1214" spread="41.6"/>
                    <measurement group_id="O4" value="1369" spread="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration of Dapro in Plasma (Cmax)</title>
        <description>Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a ‚ÄúDay 1‚Äù profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated.</description>
        <time_frame>Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration of Dapro in Plasma (Cmax)</title>
          <description>Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a ‚ÄúDay 1‚Äù profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated.</description>
          <population>PK Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.0" spread="104.0"/>
                    <measurement group_id="O2" value="141.4" spread="248.8"/>
                    <measurement group_id="O3" value="246.9" spread="311.5"/>
                    <measurement group_id="O4" value="387.3" spread="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Cmax (Tmax) and Apparent Terminal Half-life (t1/2) of Dapro</title>
        <description>Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a ‚ÄúDay 1‚Äù profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29</time_frame>
        <population>PK Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax (Tmax) and Apparent Terminal Half-life (t1/2) of Dapro</title>
          <description>Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a ‚ÄúDay 1‚Äù profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>PK Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax; n= 19, 15, 16, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.456" spread="78.9"/>
                    <measurement group_id="O2" value="2.106" spread="82.1"/>
                    <measurement group_id="O3" value="2.297" spread="96.5"/>
                    <measurement group_id="O4" value="1.718" spread="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2; n= 12, 9, 8, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.086" spread="50.0"/>
                    <measurement group_id="O2" value="1.886" spread="62.3"/>
                    <measurement group_id="O3" value="1.418" spread="58.4"/>
                    <measurement group_id="O4" value="2.897" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Study Treatment</title>
        <description>Reasons of study treatment discontinuation included adverse events (AEs), protocol deviation, participants reached protocol defined stopping criteria, physician decision and withdrawal by participants. Number of participants who discontinued study treatment are presented. Analysis was performed on Safety Population which comprised of all participants who received at least one dose of study treatment.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Treatment</title>
          <description>Reasons of study treatment discontinuation included adverse events (AEs), protocol deviation, participants reached protocol defined stopping criteria, physician decision and withdrawal by participants. Number of participants who discontinued study treatment are presented. Analysis was performed on Safety Population which comprised of all participants who received at least one dose of study treatment.</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protocol deviation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant reached stopping criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician decision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal by subject</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With AEs and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sodium, Potassium, Glucose, Calcium, Phosphate Levels in Blood at Indicated Time Points</title>
        <description>Serum sodium, potassium, glucose, corrected calcium and phosphate levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium, Potassium, Glucose, Calcium, Phosphate Levels in Blood at Indicated Time Points</title>
          <description>Serum sodium, potassium, glucose, corrected calcium and phosphate levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.8" spread="2.85"/>
                    <measurement group_id="O2" value="138.1" spread="2.31"/>
                    <measurement group_id="O3" value="138.7" spread="2.83"/>
                    <measurement group_id="O4" value="139.4" spread="2.38"/>
                    <measurement group_id="O5" value="138.4" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.7" spread="3.16"/>
                    <measurement group_id="O2" value="137.5" spread="2.72"/>
                    <measurement group_id="O3" value="138.1" spread="1.60"/>
                    <measurement group_id="O4" value="138.0" spread="2.36"/>
                    <measurement group_id="O5" value="137.2" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.8" spread="3.96"/>
                    <measurement group_id="O2" value="136.8" spread="2.70"/>
                    <measurement group_id="O3" value="137.9" spread="2.85"/>
                    <measurement group_id="O4" value="138.8" spread="2.74"/>
                    <measurement group_id="O5" value="137.1" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.2" spread="2.88"/>
                    <measurement group_id="O2" value="138.1" spread="1.77"/>
                    <measurement group_id="O3" value="137.9" spread="2.37"/>
                    <measurement group_id="O4" value="138.8" spread="2.02"/>
                    <measurement group_id="O5" value="137.6" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="0.840"/>
                    <measurement group_id="O2" value="4.73" spread="0.768"/>
                    <measurement group_id="O3" value="4.64" spread="0.826"/>
                    <measurement group_id="O4" value="4.79" spread="0.514"/>
                    <measurement group_id="O5" value="4.83" spread="0.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="0.763"/>
                    <measurement group_id="O2" value="4.77" spread="0.542"/>
                    <measurement group_id="O3" value="4.57" spread="0.635"/>
                    <measurement group_id="O4" value="4.82" spread="0.765"/>
                    <measurement group_id="O5" value="4.80" spread="0.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="0.919"/>
                    <measurement group_id="O2" value="4.87" spread="0.751"/>
                    <measurement group_id="O3" value="4.57" spread="0.472"/>
                    <measurement group_id="O4" value="4.86" spread="0.619"/>
                    <measurement group_id="O5" value="4.96" spread="0.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" spread="0.951"/>
                    <measurement group_id="O2" value="4.68" spread="0.562"/>
                    <measurement group_id="O3" value="4.59" spread="0.657"/>
                    <measurement group_id="O4" value="4.76" spread="0.752"/>
                    <measurement group_id="O5" value="4.80" spread="0.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" spread="3.088"/>
                    <measurement group_id="O2" value="6.66" spread="2.716"/>
                    <measurement group_id="O3" value="6.41" spread="3.507"/>
                    <measurement group_id="O4" value="7.05" spread="2.491"/>
                    <measurement group_id="O5" value="8.95" spread="5.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.89" spread="3.425"/>
                    <measurement group_id="O2" value="7.16" spread="2.844"/>
                    <measurement group_id="O3" value="7.03" spread="3.236"/>
                    <measurement group_id="O4" value="7.26" spread="2.852"/>
                    <measurement group_id="O5" value="8.67" spread="4.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.21" spread="4.951"/>
                    <measurement group_id="O2" value="7.49" spread="3.949"/>
                    <measurement group_id="O3" value="7.21" spread="3.953"/>
                    <measurement group_id="O4" value="7.77" spread="4.621"/>
                    <measurement group_id="O5" value="8.75" spread="5.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="3.126"/>
                    <measurement group_id="O2" value="6.72" spread="2.965"/>
                    <measurement group_id="O3" value="7.09" spread="3.533"/>
                    <measurement group_id="O4" value="6.27" spread="1.958"/>
                    <measurement group_id="O5" value="8.93" spread="4.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium corrected; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.286" spread="0.2116"/>
                    <measurement group_id="O2" value="2.270" spread="0.1244"/>
                    <measurement group_id="O3" value="2.241" spread="0.1675"/>
                    <measurement group_id="O4" value="2.219" spread="0.1589"/>
                    <measurement group_id="O5" value="2.215" spread="0.1163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium corrected; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.261" spread="0.1698"/>
                    <measurement group_id="O2" value="2.219" spread="0.1252"/>
                    <measurement group_id="O3" value="2.213" spread="0.1723"/>
                    <measurement group_id="O4" value="2.188" spread="0.1360"/>
                    <measurement group_id="O5" value="2.203" spread="0.1111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium corrected; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.205" spread="0.1431"/>
                    <measurement group_id="O2" value="2.248" spread="0.1352"/>
                    <measurement group_id="O3" value="2.244" spread="0.1577"/>
                    <measurement group_id="O4" value="2.198" spread="0.1343"/>
                    <measurement group_id="O5" value="2.225" spread="0.1810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium corrected; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.251" spread="0.1582"/>
                    <measurement group_id="O2" value="2.235" spread="0.1593"/>
                    <measurement group_id="O3" value="2.271" spread="0.1823"/>
                    <measurement group_id="O4" value="2.201" spread="0.1206"/>
                    <measurement group_id="O5" value="2.256" spread="0.1473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.608" spread="0.5143"/>
                    <measurement group_id="O2" value="1.528" spread="0.5557"/>
                    <measurement group_id="O3" value="1.498" spread="0.5265"/>
                    <measurement group_id="O4" value="1.318" spread="0.3647"/>
                    <measurement group_id="O5" value="1.566" spread="0.4269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.621" spread="0.4221"/>
                    <measurement group_id="O2" value="1.710" spread="0.3912"/>
                    <measurement group_id="O3" value="1.642" spread="0.5021"/>
                    <measurement group_id="O4" value="1.348" spread="0.3138"/>
                    <measurement group_id="O5" value="1.645" spread="0.4785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.709" spread="0.5872"/>
                    <measurement group_id="O2" value="1.592" spread="0.4121"/>
                    <measurement group_id="O3" value="1.644" spread="0.5322"/>
                    <measurement group_id="O4" value="1.453" spread="0.4489"/>
                    <measurement group_id="O5" value="1.550" spread="0.3575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.550" spread="0.5828"/>
                    <measurement group_id="O2" value="1.460" spread="0.4550"/>
                    <measurement group_id="O3" value="1.472" spread="0.4240"/>
                    <measurement group_id="O4" value="1.412" spread="0.4441"/>
                    <measurement group_id="O5" value="1.398" spread="0.4718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albumin and Protein Levels in Blood at Indicated Tme Points</title>
        <description>Serum albumin and protein levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin and Protein Levels in Blood at Indicated Tme Points</title>
          <description>Serum albumin and protein levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="2.89"/>
                    <measurement group_id="O2" value="38.6" spread="2.46"/>
                    <measurement group_id="O3" value="38.7" spread="3.84"/>
                    <measurement group_id="O4" value="38.8" spread="2.22"/>
                    <measurement group_id="O5" value="38.1" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="2.68"/>
                    <measurement group_id="O2" value="38.1" spread="2.65"/>
                    <measurement group_id="O3" value="38.4" spread="3.42"/>
                    <measurement group_id="O4" value="38.4" spread="2.52"/>
                    <measurement group_id="O5" value="37.2" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="3.22"/>
                    <measurement group_id="O2" value="37.2" spread="3.26"/>
                    <measurement group_id="O3" value="37.6" spread="3.62"/>
                    <measurement group_id="O4" value="37.4" spread="2.17"/>
                    <measurement group_id="O5" value="36.9" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="2.85"/>
                    <measurement group_id="O2" value="38.1" spread="3.02"/>
                    <measurement group_id="O3" value="37.9" spread="3.95"/>
                    <measurement group_id="O4" value="39.0" spread="3.11"/>
                    <measurement group_id="O5" value="37.5" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 1; n= 18, 20 ,20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="4.90"/>
                    <measurement group_id="O2" value="66.9" spread="5.42"/>
                    <measurement group_id="O3" value="67.4" spread="4.89"/>
                    <measurement group_id="O4" value="66.4" spread="5.16"/>
                    <measurement group_id="O5" value="65.7" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" spread="4.87"/>
                    <measurement group_id="O2" value="66.5" spread="4.88"/>
                    <measurement group_id="O3" value="67.3" spread="4.28"/>
                    <measurement group_id="O4" value="65.6" spread="5.13"/>
                    <measurement group_id="O5" value="64.3" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" spread="4.52"/>
                    <measurement group_id="O2" value="65.7" spread="4.75"/>
                    <measurement group_id="O3" value="66.0" spread="4.51"/>
                    <measurement group_id="O4" value="65.5" spread="6.50"/>
                    <measurement group_id="O5" value="65.3" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="4.25"/>
                    <measurement group_id="O2" value="67.4" spread="5.14"/>
                    <measurement group_id="O3" value="66.8" spread="4.02"/>
                    <measurement group_id="O4" value="66.7" spread="7.70"/>
                    <measurement group_id="O5" value="66.6" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (Alk. Phosph) Levels in Blood at Indicated Time Points</title>
        <description>Serum ALT, AST and alk. phosph. levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (Alk. Phosph) Levels in Blood at Indicated Time Points</title>
          <description>Serum ALT, AST and alk. phosph. levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety Population One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="9.36"/>
                    <measurement group_id="O2" value="13.4" spread="7.51"/>
                    <measurement group_id="O3" value="14.6" spread="11.39"/>
                    <measurement group_id="O4" value="10.7" spread="5.75"/>
                    <measurement group_id="O5" value="11.5" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="13.80"/>
                    <measurement group_id="O2" value="13.9" spread="10.58"/>
                    <measurement group_id="O3" value="12.4" spread="7.87"/>
                    <measurement group_id="O4" value="11.9" spread="6.58"/>
                    <measurement group_id="O5" value="8.4" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="32.34"/>
                    <measurement group_id="O2" value="12.8" spread="6.43"/>
                    <measurement group_id="O3" value="12.2" spread="6.40"/>
                    <measurement group_id="O4" value="10.9" spread="5.67"/>
                    <measurement group_id="O5" value="8.6" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="8.55"/>
                    <measurement group_id="O2" value="13.8" spread="8.03"/>
                    <measurement group_id="O3" value="12.8" spread="6.89"/>
                    <measurement group_id="O4" value="13.1" spread="5.19"/>
                    <measurement group_id="O5" value="11.2" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="5.58"/>
                    <measurement group_id="O2" value="14.2" spread="5.19"/>
                    <measurement group_id="O3" value="17.2" spread="12.31"/>
                    <measurement group_id="O4" value="14.4" spread="5.85"/>
                    <measurement group_id="O5" value="13.6" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="7.30"/>
                    <measurement group_id="O2" value="14.3" spread="5.67"/>
                    <measurement group_id="O3" value="15.0" spread="7.72"/>
                    <measurement group_id="O4" value="15.4" spread="6.33"/>
                    <measurement group_id="O5" value="12.4" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="30.04"/>
                    <measurement group_id="O2" value="13.8" spread="5.01"/>
                    <measurement group_id="O3" value="16.0" spread="8.44"/>
                    <measurement group_id="O4" value="15.0" spread="6.35"/>
                    <measurement group_id="O5" value="13.5" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="6.65"/>
                    <measurement group_id="O2" value="14.9" spread="6.07"/>
                    <measurement group_id="O3" value="17.2" spread="11.40"/>
                    <measurement group_id="O4" value="15.7" spread="6.31"/>
                    <measurement group_id="O5" value="14.3" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk. phosph; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" spread="33.07"/>
                    <measurement group_id="O2" value="112.3" spread="74.61"/>
                    <measurement group_id="O3" value="106.8" spread="84.85"/>
                    <measurement group_id="O4" value="99.4" spread="47.26"/>
                    <measurement group_id="O5" value="115.4" spread="72.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk. phosph; Day 15; n= 17, 20, 18, 22,20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.4" spread="34.70"/>
                    <measurement group_id="O2" value="115.4" spread="73.37"/>
                    <measurement group_id="O3" value="114.5" spread="82.29"/>
                    <measurement group_id="O4" value="101.5" spread="56.44"/>
                    <measurement group_id="O5" value="110.0" spread="62.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk. phosph.; Day 29; n= 17, 19, 18, 19,17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="35.07"/>
                    <measurement group_id="O2" value="120.2" spread="81.15"/>
                    <measurement group_id="O3" value="109.2" spread="83.14"/>
                    <measurement group_id="O4" value="93.5" spread="42.92"/>
                    <measurement group_id="O5" value="120.4" spread="67.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk. phosph.; Day 43; n= 15, 20, 18, 21,21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" spread="34.12"/>
                    <measurement group_id="O2" value="117.6" spread="76.61"/>
                    <measurement group_id="O3" value="113.8" spread="78.69"/>
                    <measurement group_id="O4" value="116.2" spread="96.02"/>
                    <measurement group_id="O5" value="108.6" spread="50.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin, Direct Bilirubin and Indirect Bilirubin Levels in Blood at Indicated Time Points</title>
        <description>Serum bilirubin, direct bilirubin and indirect bilirubin levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin, Direct Bilirubin and Indirect Bilirubin Levels in Blood at Indicated Time Points</title>
          <description>Serum bilirubin, direct bilirubin and indirect bilirubin levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Micromoles per liter (¬µmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="1.65"/>
                    <measurement group_id="O2" value="7.8" spread="3.11"/>
                    <measurement group_id="O3" value="6.6" spread="1.31"/>
                    <measurement group_id="O4" value="6.5" spread="1.10"/>
                    <measurement group_id="O5" value="7.2" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="3.08"/>
                    <measurement group_id="O2" value="7.1" spread="2.29"/>
                    <measurement group_id="O3" value="7.2" spread="2.67"/>
                    <measurement group_id="O4" value="6.5" spread="1.10"/>
                    <measurement group_id="O5" value="7.8" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.24"/>
                    <measurement group_id="O2" value="6.9" spread="1.93"/>
                    <measurement group_id="O3" value="7.6" spread="2.12"/>
                    <measurement group_id="O4" value="6.5" spread="1.47"/>
                    <measurement group_id="O5" value="7.8" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 43; n= 15, 20 ,18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.07"/>
                    <measurement group_id="O2" value="7.0" spread="2.38"/>
                    <measurement group_id="O3" value="7.2" spread="2.07"/>
                    <measurement group_id="O4" value="6.5" spread="1.25"/>
                    <measurement group_id="O5" value="7.5" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.17"/>
                    <measurement group_id="O2" value="1.9" spread="0.79"/>
                    <measurement group_id="O3" value="2.0" spread="1.12"/>
                    <measurement group_id="O4" value="1.9" spread="0.75"/>
                    <measurement group_id="O5" value="2.4" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.66"/>
                    <measurement group_id="O2" value="2.2" spread="0.62"/>
                    <measurement group_id="O3" value="2.4" spread="1.29"/>
                    <measurement group_id="O4" value="1.8" spread="0.85"/>
                    <measurement group_id="O5" value="2.6" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 29; n= 17, 19, 18, 19,17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.29"/>
                    <measurement group_id="O2" value="1.6" spread="1.07"/>
                    <measurement group_id="O3" value="2.7" spread="0.97"/>
                    <measurement group_id="O4" value="1.8" spread="0.63"/>
                    <measurement group_id="O5" value="2.4" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 43; n= 15, 20, 18, 21,21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.23"/>
                    <measurement group_id="O2" value="1.9" spread="0.45"/>
                    <measurement group_id="O3" value="2.3" spread="0.77"/>
                    <measurement group_id="O4" value="1.7" spread="0.72"/>
                    <measurement group_id="O5" value="2.3" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect bilirubin; Day 1; n= 18, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.22"/>
                    <measurement group_id="O2" value="5.9" spread="2.94"/>
                    <measurement group_id="O3" value="4.6" spread="0.94"/>
                    <measurement group_id="O4" value="4.6" spread="1.14"/>
                    <measurement group_id="O5" value="4.8" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect bilirubin; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.01"/>
                    <measurement group_id="O2" value="4.9" spread="2.10"/>
                    <measurement group_id="O3" value="4.8" spread="1.83"/>
                    <measurement group_id="O4" value="4.7" spread="0.98"/>
                    <measurement group_id="O5" value="5.2" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect bilirubin; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.03"/>
                    <measurement group_id="O2" value="5.4" spread="1.64"/>
                    <measurement group_id="O3" value="4.9" spread="1.57"/>
                    <measurement group_id="O4" value="4.7" spread="1.52"/>
                    <measurement group_id="O5" value="5.4" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect bilirubin; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.98"/>
                    <measurement group_id="O2" value="5.1" spread="2.38"/>
                    <measurement group_id="O3" value="4.9" spread="1.41"/>
                    <measurement group_id="O4" value="4.8" spread="1.48"/>
                    <measurement group_id="O5" value="5.2" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sodium, Potassium, Glucose, Calcium and Phosphate Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including sodium, potassium, glucose, calcium and phosphate. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sodium, Potassium, Glucose, Calcium and Phosphate Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including sodium, potassium, glucose, calcium and phosphate. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.73"/>
                    <measurement group_id="O2" value="-0.6" spread="2.62"/>
                    <measurement group_id="O3" value="-0.5" spread="2.64"/>
                    <measurement group_id="O4" value="-1.4" spread="2.06"/>
                    <measurement group_id="O5" value="-1.0" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.26"/>
                    <measurement group_id="O2" value="-1.2" spread="3.08"/>
                    <measurement group_id="O3" value="-0.9" spread="2.26"/>
                    <measurement group_id="O4" value="-0.5" spread="2.82"/>
                    <measurement group_id="O5" value="-1.2" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.06"/>
                    <measurement group_id="O2" value="0.1" spread="2.35"/>
                    <measurement group_id="O3" value="-0.6" spread="2.28"/>
                    <measurement group_id="O4" value="-0.5" spread="2.60"/>
                    <measurement group_id="O5" value="-0.6" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.462"/>
                    <measurement group_id="O2" value="0.05" spread="0.526"/>
                    <measurement group_id="O3" value="-0.09" spread="1.099"/>
                    <measurement group_id="O4" value="0.03" spread="0.944"/>
                    <measurement group_id="O5" value="-0.08" spread="0.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.744"/>
                    <measurement group_id="O2" value="0.05" spread="0.660"/>
                    <measurement group_id="O3" value="-0.14" spread="0.651"/>
                    <measurement group_id="O4" value="0.02" spread="0.640"/>
                    <measurement group_id="O5" value="0.11" spread="0.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.565"/>
                    <measurement group_id="O2" value="-0.05" spread="0.674"/>
                    <measurement group_id="O3" value="-0.06" spread="1.004"/>
                    <measurement group_id="O4" value="-0.06" spread="0.579"/>
                    <measurement group_id="O5" value="-0.02" spread="0.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="3.339"/>
                    <measurement group_id="O2" value="0.51" spread="2.959"/>
                    <measurement group_id="O3" value="0.45" spread="1.740"/>
                    <measurement group_id="O4" value="0.21" spread="1.620"/>
                    <measurement group_id="O5" value="-0.03" spread="2.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="3.771"/>
                    <measurement group_id="O2" value="0.70" spread="3.756"/>
                    <measurement group_id="O3" value="0.73" spread="1.135"/>
                    <measurement group_id="O4" value="0.61" spread="4.188"/>
                    <measurement group_id="O5" value="-0.36" spread="3.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="1.335"/>
                    <measurement group_id="O2" value="0.06" spread="3.072"/>
                    <measurement group_id="O3" value="0.52" spread="1.383"/>
                    <measurement group_id="O4" value="-0.81" spread="2.516"/>
                    <measurement group_id="O5" value="-0.12" spread="3.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.1227"/>
                    <measurement group_id="O2" value="-0.051" spread="0.1354"/>
                    <measurement group_id="O3" value="-0.026" spread="0.1439"/>
                    <measurement group_id="O4" value="-0.031" spread="0.0956"/>
                    <measurement group_id="O5" value="-0.010" spread="0.0912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.054" spread="0.1486"/>
                    <measurement group_id="O2" value="-0.025" spread="0.1129"/>
                    <measurement group_id="O3" value="-0.009" spread="0.1556"/>
                    <measurement group_id="O4" value="-0.012" spread="0.0939"/>
                    <measurement group_id="O5" value="0.001" spread="0.1019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" spread="0.1576"/>
                    <measurement group_id="O2" value="-0.035" spread="0.1261"/>
                    <measurement group_id="O3" value="0.018" spread="0.1852"/>
                    <measurement group_id="O4" value="0.001" spread="0.0742"/>
                    <measurement group_id="O5" value="0.033" spread="0.1489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.091" spread="0.4051"/>
                    <measurement group_id="O2" value="0.183" spread="0.5184"/>
                    <measurement group_id="O3" value="0.111" spread="0.5715"/>
                    <measurement group_id="O4" value="0.030" spread="0.3268"/>
                    <measurement group_id="O5" value="0.095" spread="0.3367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" spread="0.3882"/>
                    <measurement group_id="O2" value="0.011" spread="0.4932"/>
                    <measurement group_id="O3" value="0.069" spread="0.4950"/>
                    <measurement group_id="O4" value="0.129" spread="0.2740"/>
                    <measurement group_id="O5" value="-0.026" spread="0.3653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.067" spread="0.4337"/>
                    <measurement group_id="O2" value="-0.068" spread="0.5324"/>
                    <measurement group_id="O3" value="-0.053" spread="0.5400"/>
                    <measurement group_id="O4" value="0.102" spread="0.3433"/>
                    <measurement group_id="O5" value="-0.117" spread="0.5117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin and Protein Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin and Protein Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.60"/>
                    <measurement group_id="O2" value="-0.5" spread="1.64"/>
                    <measurement group_id="O3" value="0.2" spread="2.24"/>
                    <measurement group_id="O4" value="-0.5" spread="1.44"/>
                    <measurement group_id="O5" value="-1.0" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.24"/>
                    <measurement group_id="O2" value="-1.3" spread="2.03"/>
                    <measurement group_id="O3" value="-0.7" spread="2.00"/>
                    <measurement group_id="O4" value="-1.3" spread="1.85"/>
                    <measurement group_id="O5" value="-0.9" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.00"/>
                    <measurement group_id="O2" value="-0.6" spread="2.14"/>
                    <measurement group_id="O3" value="-0.7" spread="2.22"/>
                    <measurement group_id="O4" value="0.1" spread="3.85"/>
                    <measurement group_id="O5" value="-0.3" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.97"/>
                    <measurement group_id="O2" value="-0.4" spread="3.25"/>
                    <measurement group_id="O3" value="0.3" spread="3.65"/>
                    <measurement group_id="O4" value="-0.7" spread="2.35"/>
                    <measurement group_id="O5" value="-1.5" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="4.26"/>
                    <measurement group_id="O2" value="-0.8" spread="3.82"/>
                    <measurement group_id="O3" value="-1.2" spread="2.90"/>
                    <measurement group_id="O4" value="-1.0" spread="3.28"/>
                    <measurement group_id="O5" value="0.1" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="4.19"/>
                    <measurement group_id="O2" value="0.6" spread="4.38"/>
                    <measurement group_id="O3" value="-0.9" spread="3.17"/>
                    <measurement group_id="O4" value="0.3" spread="4.84"/>
                    <measurement group_id="O5" value="1.2" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ALT, AST, Alk. Phosph. Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT, AST, Alk. phosph. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ALT, AST, Alk. Phosph. Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT, AST, Alk. phosph. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="9.59"/>
                    <measurement group_id="O2" value="0.5" spread="5.65"/>
                    <measurement group_id="O3" value="-3.1" spread="5.53"/>
                    <measurement group_id="O4" value="1.1" spread="4.79"/>
                    <measurement group_id="O5" value="-3.4" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="32.39"/>
                    <measurement group_id="O2" value="-0.9" spread="4.65"/>
                    <measurement group_id="O3" value="-3.4" spread="9.83"/>
                    <measurement group_id="O4" value="-0.2" spread="3.87"/>
                    <measurement group_id="O5" value="-3.6" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="4.32"/>
                    <measurement group_id="O2" value="0.4" spread="5.29"/>
                    <measurement group_id="O3" value="-2.5" spread="8.97"/>
                    <measurement group_id="O4" value="2.2" spread="4.08"/>
                    <measurement group_id="O5" value="-0.4" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="5.70"/>
                    <measurement group_id="O2" value="0.1" spread="2.45"/>
                    <measurement group_id="O3" value="-2.7" spread="6.29"/>
                    <measurement group_id="O4" value="1.0" spread="5.26"/>
                    <measurement group_id="O5" value="-1.6" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="30.64"/>
                    <measurement group_id="O2" value="-0.3" spread="3.30"/>
                    <measurement group_id="O3" value="-1.8" spread="5.60"/>
                    <measurement group_id="O4" value="0.9" spread="3.60"/>
                    <measurement group_id="O5" value="-0.3" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="3.94"/>
                    <measurement group_id="O2" value="0.7" spread="2.49"/>
                    <measurement group_id="O3" value="-0.6" spread="7.99"/>
                    <measurement group_id="O4" value="1.5" spread="3.71"/>
                    <measurement group_id="O5" value="0.7" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk.phosph.; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="10.28"/>
                    <measurement group_id="O2" value="3.2" spread="16.13"/>
                    <measurement group_id="O3" value="2.7" spread="29.73"/>
                    <measurement group_id="O4" value="2.1" spread="17.23"/>
                    <measurement group_id="O5" value="-4.7" spread="18.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk.phosph.; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="19.31"/>
                    <measurement group_id="O2" value="5.1" spread="19.09"/>
                    <measurement group_id="O3" value="-0.9" spread="30.13"/>
                    <measurement group_id="O4" value="0.9" spread="13.47"/>
                    <measurement group_id="O5" value="-1.2" spread="28.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk.phosph.; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="17.01"/>
                    <measurement group_id="O2" value="5.4" spread="21.34"/>
                    <measurement group_id="O3" value="2.7" spread="31.96"/>
                    <measurement group_id="O4" value="18.0" spread="66.44"/>
                    <measurement group_id="O5" value="-8.4" spread="56.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bilirubin, Direct Bilirubin, Indirect Bilirubin Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including bilirubin, direct bilirubin and indirect bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the Daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bilirubin, Direct Bilirubin, Indirect Bilirubin Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical chemistry parameters including bilirubin, direct bilirubin and indirect bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the Daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>¬µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.56"/>
                    <measurement group_id="O2" value="-0.7" spread="1.49"/>
                    <measurement group_id="O3" value="0.8" spread="2.07"/>
                    <measurement group_id="O4" value="0.0" spread="1.38"/>
                    <measurement group_id="O5" value="0.5" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.97"/>
                    <measurement group_id="O2" value="-0.3" spread="1.20"/>
                    <measurement group_id="O3" value="1.0" spread="1.41"/>
                    <measurement group_id="O4" value="0.1" spread="1.56"/>
                    <measurement group_id="O5" value="0.2" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.52"/>
                    <measurement group_id="O2" value="-0.8" spread="1.51"/>
                    <measurement group_id="O3" value="0.6" spread="2.04"/>
                    <measurement group_id="O4" value="0.1" spread="1.34"/>
                    <measurement group_id="O5" value="0.4" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.11"/>
                    <measurement group_id="O2" value="0.3" spread="0.73"/>
                    <measurement group_id="O3" value="0.6" spread="0.92"/>
                    <measurement group_id="O4" value="-0.1" spread="0.97"/>
                    <measurement group_id="O5" value="0.2" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.86"/>
                    <measurement group_id="O2" value="-0.3" spread="1.00"/>
                    <measurement group_id="O3" value="0.7" spread="0.97"/>
                    <measurement group_id="O4" value="-0.1" spread="1.05"/>
                    <measurement group_id="O5" value="-0.1" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.19"/>
                    <measurement group_id="O2" value="0.0" spread="0.92"/>
                    <measurement group_id="O3" value="0.3" spread="1.03"/>
                    <measurement group_id="O4" value="-0.2" spread="1.08"/>
                    <measurement group_id="O5" value="-0.1" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect bilirubin; Day 15; n= 17, 20, 18, 22, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.46"/>
                    <measurement group_id="O2" value="-1.0" spread="1.38"/>
                    <measurement group_id="O3" value="0.2" spread="1.80"/>
                    <measurement group_id="O4" value="0.1" spread="1.44"/>
                    <measurement group_id="O5" value="0.3" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect bilirubin; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.66"/>
                    <measurement group_id="O2" value="0.0" spread="1.15"/>
                    <measurement group_id="O3" value="0.3" spread="1.71"/>
                    <measurement group_id="O4" value="0.2" spread="1.62"/>
                    <measurement group_id="O5" value="0.4" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect bilirubin; Day 43; n= 15, 20, 18, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.07"/>
                    <measurement group_id="O2" value="-0.8" spread="1.64"/>
                    <measurement group_id="O3" value="0.2" spread="1.66"/>
                    <measurement group_id="O4" value="0.3" spread="1.82"/>
                    <measurement group_id="O5" value="0.5" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leukocytes, Neutrophils, Basophils, Eosinophils,Lymphocytes, Monocytes, Platelet Levels in Blood at Indicated Time Points</title>
        <description>Serum leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelet levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Leukocytes, Neutrophils, Basophils, Eosinophils,Lymphocytes, Monocytes, Platelet Levels in Blood at Indicated Time Points</title>
          <description>Serum leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelet levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes; Day 1; n= 18, 19, 19, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" spread="1.750"/>
                    <measurement group_id="O2" value="6.07" spread="1.601"/>
                    <measurement group_id="O3" value="5.88" spread="1.510"/>
                    <measurement group_id="O4" value="6.44" spread="1.595"/>
                    <measurement group_id="O5" value="5.90" spread="1.825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.01" spread="2.140"/>
                    <measurement group_id="O2" value="5.85" spread="1.720"/>
                    <measurement group_id="O3" value="6.21" spread="1.918"/>
                    <measurement group_id="O4" value="6.52" spread="1.427"/>
                    <measurement group_id="O5" value="5.87" spread="1.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" spread="1.707"/>
                    <measurement group_id="O2" value="6.59" spread="1.890"/>
                    <measurement group_id="O3" value="5.88" spread="1.685"/>
                    <measurement group_id="O4" value="6.33" spread="1.820"/>
                    <measurement group_id="O5" value="6.11" spread="2.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; Day 43; n= 16, 20, 19, 20, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" spread="2.006"/>
                    <measurement group_id="O2" value="7.25" spread="2.520"/>
                    <measurement group_id="O3" value="6.00" spread="1.694"/>
                    <measurement group_id="O4" value="6.77" spread="2.547"/>
                    <measurement group_id="O5" value="6.42" spread="2.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 1; n= 18, 19, 19, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.030" spread="1.6128"/>
                    <measurement group_id="O2" value="4.097" spread="1.5763"/>
                    <measurement group_id="O3" value="3.522" spread="1.3492"/>
                    <measurement group_id="O4" value="3.954" spread="1.4097"/>
                    <measurement group_id="O5" value="3.785" spread="1.5024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.666" spread="1.8113"/>
                    <measurement group_id="O2" value="3.887" spread="1.5659"/>
                    <measurement group_id="O3" value="3.707" spread="1.6592"/>
                    <measurement group_id="O4" value="4.346" spread="1.2240"/>
                    <measurement group_id="O5" value="4.129" spread="1.6604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.123" spread="1.2229"/>
                    <measurement group_id="O2" value="4.591" spread="1.9586"/>
                    <measurement group_id="O3" value="3.522" spread="1.4546"/>
                    <measurement group_id="O4" value="3.978" spread="1.7026"/>
                    <measurement group_id="O5" value="4.224" spread="2.2017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.687" spread="1.8919"/>
                    <measurement group_id="O2" value="5.049" spread="2.3848"/>
                    <measurement group_id="O3" value="3.545" spread="1.4027"/>
                    <measurement group_id="O4" value="4.477" spread="2.2480"/>
                    <measurement group_id="O5" value="4.343" spread="1.6235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 1; n= 18, 19, 19, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.0131"/>
                    <measurement group_id="O2" value="0.016" spread="0.0134"/>
                    <measurement group_id="O3" value="0.025" spread="0.0174"/>
                    <measurement group_id="O4" value="0.028" spread="0.0204"/>
                    <measurement group_id="O5" value="0.017" spread="0.0142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.0214"/>
                    <measurement group_id="O2" value="0.026" spread="0.0161"/>
                    <measurement group_id="O3" value="0.022" spread="0.0139"/>
                    <measurement group_id="O4" value="0.025" spread="0.0325"/>
                    <measurement group_id="O5" value="0.024" spread="0.0140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" spread="0.0462"/>
                    <measurement group_id="O2" value="0.021" spread="0.0128"/>
                    <measurement group_id="O3" value="0.021" spread="0.0150"/>
                    <measurement group_id="O4" value="0.024" spread="0.0111"/>
                    <measurement group_id="O5" value="0.027" spread="0.0315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.0217"/>
                    <measurement group_id="O2" value="0.018" spread="0.0136"/>
                    <measurement group_id="O3" value="0.020" spread="0.0183"/>
                    <measurement group_id="O4" value="0.025" spread="0.0204"/>
                    <measurement group_id="O5" value="0.024" spread="0.0130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 1; n= 18, 19, 19, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" spread="0.1946"/>
                    <measurement group_id="O2" value="0.174" spread="0.1593"/>
                    <measurement group_id="O3" value="0.184" spread="0.1696"/>
                    <measurement group_id="O4" value="0.196" spread="0.2310"/>
                    <measurement group_id="O5" value="0.240" spread="0.2115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.1245"/>
                    <measurement group_id="O2" value="0.166" spread="0.1804"/>
                    <measurement group_id="O3" value="0.192" spread="0.2355"/>
                    <measurement group_id="O4" value="0.187" spread="0.2186"/>
                    <measurement group_id="O5" value="0.186" spread="0.1914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.176" spread="0.1917"/>
                    <measurement group_id="O2" value="0.149" spread="0.0950"/>
                    <measurement group_id="O3" value="0.145" spread="0.1136"/>
                    <measurement group_id="O4" value="0.237" spread="0.2785"/>
                    <measurement group_id="O5" value="0.185" spread="0.0798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.216" spread="0.2458"/>
                    <measurement group_id="O2" value="0.210" spread="0.1969"/>
                    <measurement group_id="O3" value="0.232" spread="0.2727"/>
                    <measurement group_id="O4" value="0.243" spread="0.2670"/>
                    <measurement group_id="O5" value="0.217" spread="0.1899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 1; n= 18, 19, 19, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.631" spread="0.4264"/>
                    <measurement group_id="O2" value="1.393" spread="0.4587"/>
                    <measurement group_id="O3" value="1.739" spread="0.6964"/>
                    <measurement group_id="O4" value="1.747" spread="0.7325"/>
                    <measurement group_id="O5" value="1.442" spread="0.4998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.735" spread="0.6699"/>
                    <measurement group_id="O2" value="1.416" spread="0.5670"/>
                    <measurement group_id="O3" value="1.842" spread="0.7381"/>
                    <measurement group_id="O4" value="1.526" spread="0.6697"/>
                    <measurement group_id="O5" value="1.206" spread="0.4609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.870" spread="0.7427"/>
                    <measurement group_id="O2" value="1.427" spread="0.4187"/>
                    <measurement group_id="O3" value="1.775" spread="0.6767"/>
                    <measurement group_id="O4" value="1.612" spread="0.5775"/>
                    <measurement group_id="O5" value="1.181" spread="0.3418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.648" spread="0.5294"/>
                    <measurement group_id="O2" value="1.509" spread="0.4386"/>
                    <measurement group_id="O3" value="1.736" spread="0.3916"/>
                    <measurement group_id="O4" value="1.721" spread="0.6644"/>
                    <measurement group_id="O5" value="1.399" spread="0.5562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 1; n= 18, 19, 20, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.401" spread="0.1511"/>
                    <measurement group_id="O2" value="0.396" spread="0.1591"/>
                    <measurement group_id="O3" value="0.435" spread="0.2703"/>
                    <measurement group_id="O4" value="0.518" spread="0.2077"/>
                    <measurement group_id="O5" value="0.421" spread="0.1722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.420" spread="0.2243"/>
                    <measurement group_id="O2" value="0.352" spread="0.1457"/>
                    <measurement group_id="O3" value="0.436" spread="0.2402"/>
                    <measurement group_id="O4" value="0.446" spread="0.2085"/>
                    <measurement group_id="O5" value="0.384" spread="0.2160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.444" spread="0.2076"/>
                    <measurement group_id="O2" value="0.457" spread="0.1503"/>
                    <measurement group_id="O3" value="0.403" spread="0.1385"/>
                    <measurement group_id="O4" value="0.600" spread="0.3465"/>
                    <measurement group_id="O5" value="0.426" spread="0.2628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.461" spread="0.1878"/>
                    <measurement group_id="O2" value="0.459" spread="0.1916"/>
                    <measurement group_id="O3" value="0.461" spread="0.2614"/>
                    <measurement group_id="O4" value="0.513" spread="0.2739"/>
                    <measurement group_id="O5" value="0.429" spread="0.2047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Day 1; n= 16, 19, 20, 19, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.0" spread="65.04"/>
                    <measurement group_id="O2" value="189.9" spread="36.70"/>
                    <measurement group_id="O3" value="198.0" spread="71.03"/>
                    <measurement group_id="O4" value="196.0" spread="61.12"/>
                    <measurement group_id="O5" value="192.3" spread="70.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Day 15; n= 17, 18, 17, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.4" spread="63.00"/>
                    <measurement group_id="O2" value="175.4" spread="44.08"/>
                    <measurement group_id="O3" value="198.5" spread="73.65"/>
                    <measurement group_id="O4" value="194.8" spread="49.08"/>
                    <measurement group_id="O5" value="181.5" spread="66.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Day 29; n= 16, 19, 17, 17, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.1" spread="76.39"/>
                    <measurement group_id="O2" value="174.7" spread="52.50"/>
                    <measurement group_id="O3" value="187.5" spread="62.66"/>
                    <measurement group_id="O4" value="198.9" spread="55.07"/>
                    <measurement group_id="O5" value="194.8" spread="81.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Day 43; n= 15, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.8" spread="61.57"/>
                    <measurement group_id="O2" value="195.8" spread="68.33"/>
                    <measurement group_id="O3" value="188.6" spread="69.28"/>
                    <measurement group_id="O4" value="194.1" spread="50.35"/>
                    <measurement group_id="O5" value="170.0" spread="44.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Hemoglobin (MCH) Levels in Blood at Indicated Time Points</title>
        <description>Serum MCH levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Hemoglobin (MCH) Levels in Blood at Indicated Time Points</title>
          <description>Serum MCH levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Pg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n= 18, 19, 20, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.19" spread="2.538"/>
                    <measurement group_id="O2" value="30.95" spread="1.889"/>
                    <measurement group_id="O3" value="30.19" spread="2.145"/>
                    <measurement group_id="O4" value="30.70" spread="1.781"/>
                    <measurement group_id="O5" value="31.46" spread="1.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.83" spread="2.100"/>
                    <measurement group_id="O2" value="2.100" spread="1.866"/>
                    <measurement group_id="O3" value="30.74" spread="1.476"/>
                    <measurement group_id="O4" value="30.85" spread="1.619"/>
                    <measurement group_id="O5" value="31.70" spread="2.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.97" spread="2.290"/>
                    <measurement group_id="O2" value="31.60" spread="2.194"/>
                    <measurement group_id="O3" value="30.56" spread="2.236"/>
                    <measurement group_id="O4" value="31.16" spread="1.729"/>
                    <measurement group_id="O5" value="31.68" spread="2.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.86" spread="1.992"/>
                    <measurement group_id="O2" value="31.04" spread="1.870"/>
                    <measurement group_id="O3" value="30.49" spread="2.155"/>
                    <measurement group_id="O4" value="30.67" spread="1.846"/>
                    <measurement group_id="O5" value="31.84" spread="2.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Hemoglobin Concentration (MCHC) Levels in Blood at Indicated Time Points</title>
        <description>Serum MCHC levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Hemoglobin Concentration (MCHC) Levels in Blood at Indicated Time Points</title>
          <description>Serum MCHC levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n= 18, 19, 20, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.9" spread="13.39"/>
                    <measurement group_id="O2" value="321.7" spread="12.61"/>
                    <measurement group_id="O3" value="319.5" spread="15.36"/>
                    <measurement group_id="O4" value="321.5" spread="12.91"/>
                    <measurement group_id="O5" value="327.6" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.5" spread="11.22"/>
                    <measurement group_id="O2" value="324.0" spread="7.79"/>
                    <measurement group_id="O3" value="324.8" spread="8.35"/>
                    <measurement group_id="O4" value="318.3" spread="12.06"/>
                    <measurement group_id="O5" value="322.7" spread="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323.3" spread="14.90"/>
                    <measurement group_id="O2" value="329.6" spread="12.61"/>
                    <measurement group_id="O3" value="325.4" spread="10.25"/>
                    <measurement group_id="O4" value="323.6" spread="8.61"/>
                    <measurement group_id="O5" value="323.9" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.9" spread="13.22"/>
                    <measurement group_id="O2" value="325.2" spread="11.98"/>
                    <measurement group_id="O3" value="325.5" spread="11.23"/>
                    <measurement group_id="O4" value="321.0" spread="11.00"/>
                    <measurement group_id="O5" value="327.0" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Volume (MCV) Levels in Blood at Indicated Time Points</title>
        <description>Serum MCV levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Volume (MCV) Levels in Blood at Indicated Time Points</title>
          <description>Serum MCV levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Femtoliter (fL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n= 18, 19, 20, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" spread="5.94"/>
                    <measurement group_id="O2" value="96.4" spread="5.68"/>
                    <measurement group_id="O3" value="94.7" spread="5.28"/>
                    <measurement group_id="O4" value="95.7" spread="4.91"/>
                    <measurement group_id="O5" value="96.1" spread="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="6.02"/>
                    <measurement group_id="O2" value="95.8" spread="6.27"/>
                    <measurement group_id="O3" value="94.8" spread="4.53"/>
                    <measurement group_id="O4" value="97.0" spread="6.41"/>
                    <measurement group_id="O5" value="98.3" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" spread="5.83"/>
                    <measurement group_id="O2" value="95.9" spread="6.05"/>
                    <measurement group_id="O3" value="94.1" spread="5.94"/>
                    <measurement group_id="O4" value="96.3" spread="4.76"/>
                    <measurement group_id="O5" value="97.8" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" spread="5.91"/>
                    <measurement group_id="O2" value="95.4" spread="5.08"/>
                    <measurement group_id="O3" value="93.7" spread="6.09"/>
                    <measurement group_id="O4" value="95.6" spread="5.27"/>
                    <measurement group_id="O5" value="97.5" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Distribution Width Levels in Blood at Indicated Time Points</title>
        <description>Erythrocyte distribution width levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Distribution Width Levels in Blood at Indicated Time Points</title>
          <description>Erythrocyte distribution width levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Percentage of width</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n= 18, 19, 20, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.13" spread="2.607"/>
                    <measurement group_id="O2" value="16.40" spread="2.082"/>
                    <measurement group_id="O3" value="15.41" spread="1.627"/>
                    <measurement group_id="O4" value="15.81" spread="2.504"/>
                    <measurement group_id="O5" value="15.68" spread="1.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.05" spread="2.088"/>
                    <measurement group_id="O2" value="15.77" spread="1.569"/>
                    <measurement group_id="O3" value="15.26" spread="1.197"/>
                    <measurement group_id="O4" value="16.30" spread="2.331"/>
                    <measurement group_id="O5" value="16.74" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.15" spread="2.530"/>
                    <measurement group_id="O2" value="15.69" spread="1.750"/>
                    <measurement group_id="O3" value="15.36" spread="1.287"/>
                    <measurement group_id="O4" value="15.76" spread="1.253"/>
                    <measurement group_id="O5" value="16.23" spread="1.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.53" spread="2.866"/>
                    <measurement group_id="O2" value="15.53" spread="2.018"/>
                    <measurement group_id="O3" value="14.95" spread="1.269"/>
                    <measurement group_id="O4" value="15.61" spread="1.297"/>
                    <measurement group_id="O5" value="15.48" spread="1.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MCH Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MCH Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Pg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.602"/>
                    <measurement group_id="O2" value="0.19" spread="0.817"/>
                    <measurement group_id="O3" value="0.27" spread="0.685"/>
                    <measurement group_id="O4" value="0.16" spread="0.520"/>
                    <measurement group_id="O5" value="0.25" spread="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.982"/>
                    <measurement group_id="O2" value="0.58" spread="1.185"/>
                    <measurement group_id="O3" value="0.42" spread="0.824"/>
                    <measurement group_id="O4" value="0.41" spread="0.744"/>
                    <measurement group_id="O5" value="0.15" spread="0.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.981"/>
                    <measurement group_id="O2" value="0.13" spread="0.948"/>
                    <measurement group_id="O3" value="0.34" spread="0.993"/>
                    <measurement group_id="O4" value="0.11" spread="0.842"/>
                    <measurement group_id="O5" value="0.29" spread="0.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MCHC Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MCHC Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="11.09"/>
                    <measurement group_id="O2" value="3.0" spread="14.21"/>
                    <measurement group_id="O3" value="3.5" spread="10.87"/>
                    <measurement group_id="O4" value="-3.2" spread="11.48"/>
                    <measurement group_id="O5" value="-5.0" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="12.81"/>
                    <measurement group_id="O2" value="7.3" spread="16.92"/>
                    <measurement group_id="O3" value="7.6" spread="8.27"/>
                    <measurement group_id="O4" value="0.8" spread="10.04"/>
                    <measurement group_id="O5" value="-4.4" spread="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="15.92"/>
                    <measurement group_id="O2" value="3.0" spread="16.53"/>
                    <measurement group_id="O3" value="6.0" spread="11.44"/>
                    <measurement group_id="O4" value="-1.0" spread="12.12"/>
                    <measurement group_id="O5" value="-0.3" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MCV Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MCV Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.98"/>
                    <measurement group_id="O2" value="-0.2" spread="3.39"/>
                    <measurement group_id="O3" value="-0.3" spread="2.57"/>
                    <measurement group_id="O4" value="1.3" spread="3.15"/>
                    <measurement group_id="O5" value="2.2" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="3.24"/>
                    <measurement group_id="O2" value="-0.5" spread="2.86"/>
                    <measurement group_id="O3" value="-0.9" spread="2.36"/>
                    <measurement group_id="O4" value="0.9" spread="2.54"/>
                    <measurement group_id="O5" value="1.6" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.15"/>
                    <measurement group_id="O2" value="-0.7" spread="3.37"/>
                    <measurement group_id="O3" value="-0.8" spread="3.28"/>
                    <measurement group_id="O4" value="0.6" spread="3.06"/>
                    <measurement group_id="O5" value="0.9" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erythrocyte Distribution Width Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte distribution width. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte Distribution Width Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte distribution width. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Percentage of width</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="1.025"/>
                    <measurement group_id="O2" value="-0.48" spread="1.276"/>
                    <measurement group_id="O3" value="-0.09" spread="1.047"/>
                    <measurement group_id="O4" value="0.54" spread="1.162"/>
                    <measurement group_id="O5" value="1.06" spread="1.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="1.019"/>
                    <measurement group_id="O2" value="-0.64" spread="1.332"/>
                    <measurement group_id="O3" value="-0.23" spread="1.021"/>
                    <measurement group_id="O4" value="0.58" spread="1.202"/>
                    <measurement group_id="O5" value="0.40" spread="1.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="1.329"/>
                    <measurement group_id="O2" value="-0.74" spread="1.728"/>
                    <measurement group_id="O3" value="-0.50" spread="1.094"/>
                    <measurement group_id="O4" value="0.23" spread="1.410"/>
                    <measurement group_id="O5" value="-0.22" spread="1.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Leukocytes, Neutrophils, Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets Levels</title>
        <description>Blood samples were collected from participants to evaluate clinical hematology parameters including leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes, platelets. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Leukocytes, Neutrophils, Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets Levels</title>
          <description>Blood samples were collected from participants to evaluate clinical hematology parameters including leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes, platelets. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="1.271"/>
                    <measurement group_id="O2" value="-0.21" spread="1.051"/>
                    <measurement group_id="O3" value="0.40" spread="1.116"/>
                    <measurement group_id="O4" value="-0.03" spread="1.476"/>
                    <measurement group_id="O5" value="-0.03" spread="1.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; Day 29; n= 16, 19, 17, 18, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="1.849"/>
                    <measurement group_id="O2" value="0.40" spread="1.784"/>
                    <measurement group_id="O3" value="0.00" spread="1.084"/>
                    <measurement group_id="O4" value="-0.14" spread="1.701"/>
                    <measurement group_id="O5" value="0.20" spread="1.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; Day 43; n= 16, 20, 19, 20, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="1.041"/>
                    <measurement group_id="O2" value="1.08" spread="1.662"/>
                    <measurement group_id="O3" value="0.23" spread="1.101"/>
                    <measurement group_id="O4" value="0.21" spread="2.615"/>
                    <measurement group_id="O5" value="0.67" spread="1.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.391" spread="1.2323"/>
                    <measurement group_id="O2" value="-0.146" spread="0.9163"/>
                    <measurement group_id="O3" value="0.280" spread="1.0681"/>
                    <measurement group_id="O4" value="0.259" spread="1.3874"/>
                    <measurement group_id="O5" value="0.344" spread="1.2469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.237" spread="1.6283"/>
                    <measurement group_id="O2" value="0.469" spread="1.5717"/>
                    <measurement group_id="O3" value="-0.021" spread="1.0157"/>
                    <measurement group_id="O4" value="-0.009" spread="1.8718"/>
                    <measurement group_id="O5" value="0.273" spread="1.5729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.423" spread="1.0535"/>
                    <measurement group_id="O2" value="0.904" spread="1.3737"/>
                    <measurement group_id="O3" value="0.112" spread="1.0449"/>
                    <measurement group_id="O4" value="0.504" spread="2.3110"/>
                    <measurement group_id="O5" value="0.691" spread="1.5221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.0302"/>
                    <measurement group_id="O2" value="0.009" spread="0.0200"/>
                    <measurement group_id="O3" value="-0.002" spread="0.0210"/>
                    <measurement group_id="O4" value="-0.002" spread="0.0383"/>
                    <measurement group_id="O5" value="0.007" spread="0.0102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" spread="0.0510"/>
                    <measurement group_id="O2" value="0.006" spread="0.0195"/>
                    <measurement group_id="O3" value="-0.004" spread="0.0187"/>
                    <measurement group_id="O4" value="0.000" spread="0.0242"/>
                    <measurement group_id="O5" value="0.012" spread="0.0328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.0268"/>
                    <measurement group_id="O2" value="0.001" spread="0.0148"/>
                    <measurement group_id="O3" value="-0.004" spread="0.0203"/>
                    <measurement group_id="O4" value="-0.001" spread="0.0228"/>
                    <measurement group_id="O5" value="0.007" spread="0.0192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" spread="0.0698"/>
                    <measurement group_id="O2" value="-0.017" spread="0.1313"/>
                    <measurement group_id="O3" value="-0.006" spread="0.1345"/>
                    <measurement group_id="O4" value="-0.006" spread="0.1183"/>
                    <measurement group_id="O5" value="-0.053" spread="0.1478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.0859"/>
                    <measurement group_id="O2" value="-0.002" spread="0.1226"/>
                    <measurement group_id="O3" value="-0.006" spread="0.1129"/>
                    <measurement group_id="O4" value="0.025" spread="0.0990"/>
                    <measurement group_id="O5" value="0.007" spread="0.0880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" spread="0.1193"/>
                    <measurement group_id="O2" value="0.030" spread="0.1439"/>
                    <measurement group_id="O3" value="0.051" spread="0.1647"/>
                    <measurement group_id="O4" value="0.021" spread="0.0984"/>
                    <measurement group_id="O5" value="-0.024" spread="0.1876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.082" spread="0.4256"/>
                    <measurement group_id="O2" value="-0.019" spread="0.3163"/>
                    <measurement group_id="O3" value="0.106" spread="0.4617"/>
                    <measurement group_id="O4" value="-0.208" spread="0.5095"/>
                    <measurement group_id="O5" value="-0.236" spread="0.4298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.194" spread="0.6605"/>
                    <measurement group_id="O2" value="0.026" spread="0.4130"/>
                    <measurement group_id="O3" value="0.019" spread="0.4421"/>
                    <measurement group_id="O4" value="-0.074" spread="0.7018"/>
                    <measurement group_id="O5" value="-0.154" spread="0.3058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.3427"/>
                    <measurement group_id="O2" value="0.061" spread="0.3332"/>
                    <measurement group_id="O3" value="0.007" spread="0.4824"/>
                    <measurement group_id="O4" value="-0.064" spread="0.4759"/>
                    <measurement group_id="O5" value="-0.041" spread="0.2801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 15; n= 17, 19, 17, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.1518"/>
                    <measurement group_id="O2" value="-0.042" spread="0.1504"/>
                    <measurement group_id="O3" value="-0.016" spread="0.2285"/>
                    <measurement group_id="O4" value="-0.068" spread="0.1895"/>
                    <measurement group_id="O5" value="-0.037" spread="0.1460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 29; n= 16, 18, 17, 17, 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.1553"/>
                    <measurement group_id="O2" value="0.053" spread="0.1483"/>
                    <measurement group_id="O3" value="-0.031" spread="0.2194"/>
                    <measurement group_id="O4" value="0.077" spread="0.2532"/>
                    <measurement group_id="O5" value="0.015" spread="0.1878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 43; n= 16, 20, 19, 19, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.1631"/>
                    <measurement group_id="O2" value="0.065" spread="0.1629"/>
                    <measurement group_id="O3" value="0.026" spread="0.2652"/>
                    <measurement group_id="O4" value="-0.021" spread="0.1855"/>
                    <measurement group_id="O5" value="0.023" spread="0.1249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Day 15; n= 17, 18, 17, 20, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" spread="26.24"/>
                    <measurement group_id="O2" value="-16.2" spread="27.46"/>
                    <measurement group_id="O3" value="-3.2" spread="38.13"/>
                    <measurement group_id="O4" value="-3.3" spread="27.78"/>
                    <measurement group_id="O5" value="-10.8" spread="31.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Day 29; n= 16, 18, 17, 17, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" spread="40.58"/>
                    <measurement group_id="O2" value="-12.8" spread="36.55"/>
                    <measurement group_id="O3" value="-18.1" spread="29.63"/>
                    <measurement group_id="O4" value="1.3" spread="35.58"/>
                    <measurement group_id="O5" value="-2.4" spread="33.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet; Day 43; n= 15, 19, 19, 21, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="37.30"/>
                    <measurement group_id="O2" value="4.4" spread="50.34"/>
                    <measurement group_id="O3" value="-10.4" spread="35.12"/>
                    <measurement group_id="O4" value="-1.6" spread="30.95"/>
                    <measurement group_id="O5" value="-7.1" spread="31.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Indicated Time Points</title>
        <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT interval. Number of participants who had abnormal non clinically significant (NCS) and abnormal clinically significant (CS) ECG findings at Baseline (Week -4) and Day 29 are presented.</description>
        <time_frame>Up to Day 29</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Indicated Time Points</title>
          <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT interval. Number of participants who had abnormal non clinically significant (NCS) and abnormal clinically significant (CS) ECG findings at Baseline (Week -4) and Day 29 are presented.</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline(Week -4);Abnormal; NCS;n=19,20,20,22,22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline(Week-4);Abnormal;CS;n=19,20,20,22,22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; Abnormal; NCS; n=17,19,18,19,17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; Abnormal; CS; n=17,19,18,19,17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ECG Mean Heart Rate</title>
        <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure HR. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ECG Mean Heart Rate</title>
          <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure HR. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="8.66"/>
                    <measurement group_id="O2" value="0.5" spread="10.53"/>
                    <measurement group_id="O3" value="1.1" spread="7.40"/>
                    <measurement group_id="O4" value="2.2" spread="7.51"/>
                    <measurement group_id="O5" value="0.9" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval and QTcB</title>
        <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure PR interval, QRS duration, QT interval and QTcB. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval and QTcB</title>
          <description>Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure PR interval, QRS duration, QT interval and QTcB. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval; n= 17, 18, 18, 17, 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="16.86"/>
                    <measurement group_id="O2" value="7.3" spread="12.37"/>
                    <measurement group_id="O3" value="-3.3" spread="23.04"/>
                    <measurement group_id="O4" value="2.1" spread="27.13"/>
                    <measurement group_id="O5" value="-11.5" spread="24.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="14.05"/>
                    <measurement group_id="O2" value="-5.7" spread="13.36"/>
                    <measurement group_id="O3" value="-4.7" spread="47.01"/>
                    <measurement group_id="O4" value="1.7" spread="14.33"/>
                    <measurement group_id="O5" value="2.5" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="27.16"/>
                    <measurement group_id="O2" value="0.7" spread="31.11"/>
                    <measurement group_id="O3" value="-19.2" spread="62.37"/>
                    <measurement group_id="O4" value="-1.4" spread="17.72"/>
                    <measurement group_id="O5" value="-8.2" spread="33.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="30.84"/>
                    <measurement group_id="O2" value="5.6" spread="17.40"/>
                    <measurement group_id="O3" value="-3.7" spread="44.86"/>
                    <measurement group_id="O4" value="1.1" spread="20.84"/>
                    <measurement group_id="O5" value="-5.7" spread="31.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Pre-dialysis and Post-dialysis</title>
        <description>Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair at specific time points. SBP and DBP were measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Pre-dialysis and Post-dialysis</title>
          <description>Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair at specific time points. SBP and DBP were measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP; pre-dialysis; Day 1; n= 19, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.5" spread="22.15"/>
                    <measurement group_id="O2" value="136.6" spread="15.39"/>
                    <measurement group_id="O3" value="149.2" spread="26.36"/>
                    <measurement group_id="O4" value="144.1" spread="24.27"/>
                    <measurement group_id="O5" value="144.1" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.8" spread="24.12"/>
                    <measurement group_id="O2" value="138.3" spread="16.14"/>
                    <measurement group_id="O3" value="139.0" spread="22.77"/>
                    <measurement group_id="O4" value="146.6" spread="20.75"/>
                    <measurement group_id="O5" value="142.3" spread="14.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.0" spread="22.08"/>
                    <measurement group_id="O2" value="133.1" spread="18.65"/>
                    <measurement group_id="O3" value="143.1" spread="23.21"/>
                    <measurement group_id="O4" value="144.2" spread="23.27"/>
                    <measurement group_id="O5" value="148.7" spread="19.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.0" spread="22.01"/>
                    <measurement group_id="O2" value="137.9" spread="13.21"/>
                    <measurement group_id="O3" value="142.0" spread="24.23"/>
                    <measurement group_id="O4" value="149.0" spread="23.32"/>
                    <measurement group_id="O5" value="147.1" spread="19.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-dialysis; Day 1; n= 19, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" spread="14.84"/>
                    <measurement group_id="O2" value="68.8" spread="11.02"/>
                    <measurement group_id="O3" value="73.3" spread="12.96"/>
                    <measurement group_id="O4" value="71.8" spread="14.38"/>
                    <measurement group_id="O5" value="72.2" spread="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="17.76"/>
                    <measurement group_id="O2" value="70.0" spread="11.92"/>
                    <measurement group_id="O3" value="70.1" spread="10.50"/>
                    <measurement group_id="O4" value="73.5" spread="13.69"/>
                    <measurement group_id="O5" value="69.7" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="15.43"/>
                    <measurement group_id="O2" value="63.5" spread="13.55"/>
                    <measurement group_id="O3" value="70.9" spread="12.86"/>
                    <measurement group_id="O4" value="73.3" spread="13.17"/>
                    <measurement group_id="O5" value="72.7" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="14.73"/>
                    <measurement group_id="O2" value="66.8" spread="11.94"/>
                    <measurement group_id="O3" value="69.9" spread="13.54"/>
                    <measurement group_id="O4" value="77.9" spread="16.03"/>
                    <measurement group_id="O5" value="72.8" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-dialysis; Day 1; n= 19, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.6" spread="18.57"/>
                    <measurement group_id="O2" value="137.0" spread="22.10"/>
                    <measurement group_id="O3" value="139.9" spread="22.24"/>
                    <measurement group_id="O4" value="136.7" spread="21.15"/>
                    <measurement group_id="O5" value="140.1" spread="20.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.6" spread="21.83"/>
                    <measurement group_id="O2" value="135.5" spread="21.63"/>
                    <measurement group_id="O3" value="137.7" spread="23.02"/>
                    <measurement group_id="O4" value="137.4" spread="17.58"/>
                    <measurement group_id="O5" value="140.9" spread="15.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.7" spread="26.04"/>
                    <measurement group_id="O2" value="130.1" spread="18.50"/>
                    <measurement group_id="O3" value="133.7" spread="23.88"/>
                    <measurement group_id="O4" value="142.8" spread="23.96"/>
                    <measurement group_id="O5" value="147.8" spread="19.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.5" spread="22.74"/>
                    <measurement group_id="O2" value="135.8" spread="21.05"/>
                    <measurement group_id="O3" value="130.4" spread="15.47"/>
                    <measurement group_id="O4" value="145.2" spread="20.66"/>
                    <measurement group_id="O5" value="137.5" spread="22.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-dialysis; Day 1; n= 19, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="15.11"/>
                    <measurement group_id="O2" value="67.9" spread="11.49"/>
                    <measurement group_id="O3" value="68.7" spread="11.64"/>
                    <measurement group_id="O4" value="71.1" spread="12.92"/>
                    <measurement group_id="O5" value="71.5" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="16.41"/>
                    <measurement group_id="O2" value="70.1" spread="12.84"/>
                    <measurement group_id="O3" value="67.8" spread="11.10"/>
                    <measurement group_id="O4" value="71.3" spread="11.07"/>
                    <measurement group_id="O5" value="71.1" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="15.11"/>
                    <measurement group_id="O2" value="64.4" spread="9.83"/>
                    <measurement group_id="O3" value="67.9" spread="12.00"/>
                    <measurement group_id="O4" value="72.4" spread="12.43"/>
                    <measurement group_id="O5" value="72.9" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" spread="15.24"/>
                    <measurement group_id="O2" value="67.4" spread="10.90"/>
                    <measurement group_id="O3" value="67.4" spread="11.24"/>
                    <measurement group_id="O4" value="72.9" spread="12.60"/>
                    <measurement group_id="O5" value="75.3" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate Values at Pre-dialysis and Post-dialysis</title>
        <description>Vital sign measurements including pulse rate values were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate Values at Pre-dialysis and Post-dialysis</title>
          <description>Vital sign measurements including pulse rate values were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis; Day 1; n= 19, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="7.95"/>
                    <measurement group_id="O2" value="69.9" spread="9.18"/>
                    <measurement group_id="O3" value="66.7" spread="7.01"/>
                    <measurement group_id="O4" value="71.4" spread="11.25"/>
                    <measurement group_id="O5" value="76.5" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="10.31"/>
                    <measurement group_id="O2" value="67.3" spread="9.20"/>
                    <measurement group_id="O3" value="68.3" spread="7.51"/>
                    <measurement group_id="O4" value="72.1" spread="11.89"/>
                    <measurement group_id="O5" value="75.1" spread="12.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="8.31"/>
                    <measurement group_id="O2" value="70.3" spread="11.54"/>
                    <measurement group_id="O3" value="69.6" spread="9.53"/>
                    <measurement group_id="O4" value="70.8" spread="9.91"/>
                    <measurement group_id="O5" value="73.4" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" spread="9.17"/>
                    <measurement group_id="O2" value="69.9" spread="9.34"/>
                    <measurement group_id="O3" value="66.9" spread="6.74"/>
                    <measurement group_id="O4" value="71.3" spread="10.08"/>
                    <measurement group_id="O5" value="75.8" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis; Day 1; n= 19, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="11.54"/>
                    <measurement group_id="O2" value="68.7" spread="11.19"/>
                    <measurement group_id="O3" value="66.3" spread="8.37"/>
                    <measurement group_id="O4" value="73.2" spread="12.77"/>
                    <measurement group_id="O5" value="78.8" spread="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="12.69"/>
                    <measurement group_id="O2" value="67.7" spread="12.24"/>
                    <measurement group_id="O3" value="70.1" spread="12.49"/>
                    <measurement group_id="O4" value="73.0" spread="12.07"/>
                    <measurement group_id="O5" value="78.1" spread="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" spread="7.10"/>
                    <measurement group_id="O2" value="69.9" spread="9.60"/>
                    <measurement group_id="O3" value="68.8" spread="11.29"/>
                    <measurement group_id="O4" value="72.2" spread="9.52"/>
                    <measurement group_id="O5" value="77.4" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" spread="12.04"/>
                    <measurement group_id="O2" value="69.1" spread="10.21"/>
                    <measurement group_id="O3" value="68.0" spread="10.28"/>
                    <measurement group_id="O4" value="71.9" spread="11.02"/>
                    <measurement group_id="O5" value="77.3" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Values at Post-dialysis</title>
        <description>Vital sign measurements including weight values were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Values at Post-dialysis</title>
          <description>Vital sign measurements including weight values were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; n= 19, 20, 20, 22, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.38" spread="25.941"/>
                    <measurement group_id="O2" value="80.04" spread="25.996"/>
                    <measurement group_id="O3" value="78.83" spread="21.331"/>
                    <measurement group_id="O4" value="79.38" spread="23.345"/>
                    <measurement group_id="O5" value="76.03" spread="16.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.24" spread="26.652"/>
                    <measurement group_id="O2" value="80.00" spread="25.887"/>
                    <measurement group_id="O3" value="79.82" spread="22.200"/>
                    <measurement group_id="O4" value="79.44" spread="23.500"/>
                    <measurement group_id="O5" value="75.55" spread="17.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.22" spread="27.198"/>
                    <measurement group_id="O2" value="81.04" spread="25.925"/>
                    <measurement group_id="O3" value="80.02" spread="22.286"/>
                    <measurement group_id="O4" value="82.66" spread="23.036"/>
                    <measurement group_id="O5" value="76.07" spread="18.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.93" spread="27.589"/>
                    <measurement group_id="O2" value="80.21" spread="26.683"/>
                    <measurement group_id="O3" value="79.25" spread="21.757"/>
                    <measurement group_id="O4" value="80.64" spread="23.347"/>
                    <measurement group_id="O5" value="73.66" spread="11.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SBP and DBP Values at Pre-dialysis and Post-dialysis</title>
        <description>Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair. SBP and DBP were measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as SBP and DBP value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP and DBP Values at Pre-dialysis and Post-dialysis</title>
          <description>Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair. SBP and DBP were measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as SBP and DBP value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="22.03"/>
                    <measurement group_id="O2" value="1.7" spread="14.14"/>
                    <measurement group_id="O3" value="-5.6" spread="14.77"/>
                    <measurement group_id="O4" value="2.5" spread="20.68"/>
                    <measurement group_id="O5" value="-1.4" spread="16.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="20.32"/>
                    <measurement group_id="O2" value="-3.9" spread="19.72"/>
                    <measurement group_id="O3" value="-4.7" spread="18.17"/>
                    <measurement group_id="O4" value="1.3" spread="17.51"/>
                    <measurement group_id="O5" value="4.5" spread="20.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="21.34"/>
                    <measurement group_id="O2" value="1.2" spread="17.14"/>
                    <measurement group_id="O3" value="-6.2" spread="13.83"/>
                    <measurement group_id="O4" value="3.3" spread="19.47"/>
                    <measurement group_id="O5" value="4.3" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="21.39"/>
                    <measurement group_id="O2" value="-3.6" spread="20.13"/>
                    <measurement group_id="O3" value="6.1" spread="20.81"/>
                    <measurement group_id="O4" value="5.7" spread="21.07"/>
                    <measurement group_id="O5" value="-0.7" spread="22.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="19.72"/>
                    <measurement group_id="O2" value="-9.4" spread="18.50"/>
                    <measurement group_id="O3" value="0.8" spread="24.79"/>
                    <measurement group_id="O4" value="9.3" spread="19.03"/>
                    <measurement group_id="O5" value="4.0" spread="19.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="22.22"/>
                    <measurement group_id="O2" value="-3.2" spread="21.71"/>
                    <measurement group_id="O3" value="-3.6" spread="17.88"/>
                    <measurement group_id="O4" value="12.0" spread="20.19"/>
                    <measurement group_id="O5" value="4.7" spread="20.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="10.57"/>
                    <measurement group_id="O2" value="1.2" spread="8.85"/>
                    <measurement group_id="O3" value="-1.7" spread="9.78"/>
                    <measurement group_id="O4" value="1.8" spread="12.68"/>
                    <measurement group_id="O5" value="-2.1" spread="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="11.09"/>
                    <measurement group_id="O2" value="-4.7" spread="10.04"/>
                    <measurement group_id="O3" value="-3.0" spread="8.99"/>
                    <measurement group_id="O4" value="1.4" spread="10.50"/>
                    <measurement group_id="O5" value="-0.1" spread="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="8.80"/>
                    <measurement group_id="O2" value="-2.0" spread="9.47"/>
                    <measurement group_id="O3" value="-3.1" spread="11.06"/>
                    <measurement group_id="O4" value="5.2" spread="15.08"/>
                    <measurement group_id="O5" value="2.1" spread="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="11.41"/>
                    <measurement group_id="O2" value="2.4" spread="7.71"/>
                    <measurement group_id="O3" value="-2.9" spread="11.11"/>
                    <measurement group_id="O4" value="3.6" spread="9.84"/>
                    <measurement group_id="O5" value="-0.8" spread="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="12.93"/>
                    <measurement group_id="O2" value="-2.5" spread="8.52"/>
                    <measurement group_id="O3" value="-3.2" spread="11.61"/>
                    <measurement group_id="O4" value="4.1" spread="9.33"/>
                    <measurement group_id="O5" value="0.2" spread="10.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="10.07"/>
                    <measurement group_id="O2" value="-0.3" spread="9.53"/>
                    <measurement group_id="O3" value="-3.8" spread="12.13"/>
                    <measurement group_id="O4" value="4.5" spread="9.99"/>
                    <measurement group_id="O5" value="4.8" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate Value at Pre-dialysis and Post-dialysis</title>
        <description>Vital sign measurements including pulse rate were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as pulse rate value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as pulse rate value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate Value at Pre-dialysis and Post-dialysis</title>
          <description>Vital sign measurements including pulse rate were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as pulse rate value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as pulse rate value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="9.50"/>
                    <measurement group_id="O2" value="-2.6" spread="8.46"/>
                    <measurement group_id="O3" value="2.3" spread="5.76"/>
                    <measurement group_id="O4" value="0.7" spread="11.46"/>
                    <measurement group_id="O5" value="-1.4" spread="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="6.92"/>
                    <measurement group_id="O2" value="0.9" spread="12.86"/>
                    <measurement group_id="O3" value="3.4" spread="7.58"/>
                    <measurement group_id="O4" value="0.5" spread="10.01"/>
                    <measurement group_id="O5" value="-3.0" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="9.59"/>
                    <measurement group_id="O2" value="0.1" spread="6.57"/>
                    <measurement group_id="O3" value="0.8" spread="6.11"/>
                    <measurement group_id="O4" value="-0.6" spread="10.03"/>
                    <measurement group_id="O5" value="0.2" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis; Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="11.61"/>
                    <measurement group_id="O2" value="-1.2" spread="12.86"/>
                    <measurement group_id="O3" value="1.1" spread="10.15"/>
                    <measurement group_id="O4" value="0.5" spread="8.00"/>
                    <measurement group_id="O5" value="4.4" spread="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis; Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="9.13"/>
                    <measurement group_id="O2" value="1.5" spread="13.13"/>
                    <measurement group_id="O3" value="-0.8" spread="9.79"/>
                    <measurement group_id="O4" value="2.6" spread="9.04"/>
                    <measurement group_id="O5" value="6.0" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis; Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="8.67"/>
                    <measurement group_id="O2" value="0.3" spread="12.96"/>
                    <measurement group_id="O3" value="-0.8" spread="9.32"/>
                    <measurement group_id="O4" value="-0.1" spread="9.08"/>
                    <measurement group_id="O5" value="3.9" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight at Post-dialysis</title>
        <description>Vital sign measurements including weight were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>Dapro 10 mg</title>
            <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Dapro 15 mg</title>
            <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Dapro 25 mg</title>
            <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
          </group>
          <group group_id="O5">
            <title>Dapro 30 mg</title>
            <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Post-dialysis</title>
          <description>Vital sign measurements including weight were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>Safety Population. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15; n= 17, 20, 18, 22, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.634"/>
                    <measurement group_id="O2" value="0.16" spread="0.971"/>
                    <measurement group_id="O3" value="-0.01" spread="0.617"/>
                    <measurement group_id="O4" value="0.06" spread="0.799"/>
                    <measurement group_id="O5" value="-0.31" spread="1.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29; n= 17, 19, 18, 19, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="1.053"/>
                    <measurement group_id="O2" value="-0.05" spread="1.583"/>
                    <measurement group_id="O3" value="-1.23" spread="5.913"/>
                    <measurement group_id="O4" value="-0.16" spread="1.046"/>
                    <measurement group_id="O5" value="-0.19" spread="1.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43; n= 16, 20, 19, 21, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.665"/>
                    <measurement group_id="O2" value="0.37" spread="2.760"/>
                    <measurement group_id="O3" value="-1.39" spread="5.759"/>
                    <measurement group_id="O4" value="0.15" spread="1.472"/>
                    <measurement group_id="O5" value="0.33" spread="2.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-therapy serious adverse events (SAEs) and non-serious adverse events (AEs) are presented from the start of study treatment to the end of the 29-day study treatment period plus 1 day, inclusive; an average of 30 days.</time_frame>
      <desc>On-therapy SAEs and non-serious AEs are reported for members of the safety Population, comprised of all participants who received at least one dose of investigational drug. One participant who was randomized to the placebo group, erroneously received 25mg daprodustat treatment throughout the 29-day treatment period. This subject is counted within the daprodustat 25mg treatment group for all PK population and safety population analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Randomized participants received placebo tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="E2">
          <title>Dapro 10 mg</title>
          <description>Randomized participants received dapro 10 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="E3">
          <title>Dapro 15 mg</title>
          <description>Randomized participants received dapro 15 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="E4">
          <title>Dapro 25 mg</title>
          <description>Randomized participants received dapro 25 mg tablet via oral route three times weekly for 29 days.</description>
        </group>
        <group group_id="E5">
          <title>Dapro 30 mg</title>
          <description>Randomized participants received dapro 30 mg tablet via oral route three times weekly for 29 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mesenteric artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

